MRP Capital Investments’s Royalty Pharma RPRX Stock Holding History

MRP Capital Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$449K	Buy	+8,000	New	+$416K	0.33%	63
2026 Q1	–	Sell	-8,200	Closed	-$317K	–	223
2025 Q4	$317K	Buy	8,200 +3,900	+91%	+$149K	0.27%	74
2025 Q3	$155K	Hold	4,300	–	–	0.13%	101
2025 Q2	$155K	Buy	4,300 +180	+4%	+$5.96K	0.11%	92
2025 Q1	$128K	Hold	4,120	–	–	0.12%	105
2024 Q4	$105K	Sell	4,120 -2,000	-33%	-$53K	0.1%	104
2024 Q3	$173K	Buy	+6,120	New	+$170K	0.16%	98
2023 Q3	–	Sell	-7,200	Closed	-$221K	–	189
2023 Q2	$221K	Buy	7,200 +200	+3%	+$6.77K	0.22%	100
2023 Q1	$252K	Hold	7,000	–	–	0.28%	79
2022 Q4	$277K	Buy	+7,000	New	+$292K	0.31%	74

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MRP Capital Investments's RPRX Position: Q2 2026 in Review

MRP Capital Investments opened a new position in Royalty Pharma (RPRX) in Q2 2026: 8,000 shares worth $449K. The stake represents 0.33% of the portfolio and ranks #63 among its holdings. This is a return to the name: MRP Capital Investments previously reported a position in RPRX as recently as Q4 2025.

MRP Capital Investments first reported a position in RPRX in Q4 2022 and has held it in 10 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

MRP Capital Investments held 8,000 shares of Royalty Pharma worth $449K as of Q2 2026.
Royalty Pharma was a new MRP Capital Investments position in Q2 2026.
Royalty Pharma made up 0.33% of MRP Capital Investments's portfolio in Q2 2026, its #63 holding.
MRP Capital Investments first reported a position in Royalty Pharma in Q4 2022 and has held it in 10 quarters since.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on MRP Capital Investments's 13F filing for Q2 2026, filed 10 Aug 2026.